All News Prelude Therapeutics Incorporated

Equities

PRLD

US74065P1012

Real-time Estimate Cboe BZX Other stock markets 07:23:51 18/06/2024 pm IST			5-day change	1st Jan Change
3.945 ^USD	+0.38%		-0.76%	-7.96%

12/06	Transcript : Prelude Therapeutics Incorporated Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 10:40 AM
31/05	Prelude Therapeutics Files for $400 Million Mixed Shelf	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transcript : Prelude Therapeutics Incorporated Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 10:40 AM	12/06
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences	03/06	GL
Prelude Therapeutics Files for $400 Million Mixed Shelf	31/05	MT
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference	09/05	GL
Prelude Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	07/05	GL
Bryant D. Lim to Serve as Principal Financial Officer and Principal Accounting Officer of Prelude Therapeutics Incorporated	11/04	CI
Prelude Therapeutics Incorporated Announces Chief Financial Officer Changes	11/04	CI
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting	10/04	GL
Transcript : Prelude Therapeutics Incorporated Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 03:05 PM	14/03
JMP Securities Starts Prelude Therapeutics With Market Outperform Rating, $7 Price Target	13/03	MT
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting	06/03	GL
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference	01/03	GL
HC Wainwright Downgrades Prelude Therapeutics to Neutral From Buy, Price Target is $5	20/02	MT
Prelude Therapeutics Shares Surge Following Shelf Registration	16/02	MT
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024	16/02	GL
Prelude Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	16/02	CI
Transcript : Prelude Therapeutics Incorporated - Special Call	13/02
Morgan Stanley Downgrades Prelude Therapeutics to Underweight From Equalweight, Cuts Price Target to $4 From $10	19/12	MT
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) dropped from NASDAQ Biotechnology Index	15/12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Prelude Therapeutics Incorporated

Equities

PRLD

US74065P1012

All News

Filters